U.S. markets closed

Enzon Pharmaceuticals, Inc. (ENZN)

Other OTC - Other OTC Delayed Price. Currency in USD
0.1050-0.0000 (-0.02%)
At close: 11:07AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1050
Bid0.3800 x 3000
Ask1.4100 x 200
Day's Range0.1050 - 0.1050
52 Week Range0.0900 - 0.2800
Avg. Volume14,922
Market Cap7.791M
Beta (5Y Monthly)0.42
PE Ratio (TTM)
EPS (TTM)0.0000
Earnings DateFeb 05, 2024 - Feb 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSep 30, 2019
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ENZN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    NBIX: Raising target price to $118.00NEUROCRINE BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $118.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • We're sorry we weren't able to find anything about this topic.